Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors

Peng Wu¹, Yi Su², Xianghong Guan¹, Xiaowen Liu², Jiankang Zhang¹, Xiaowu Dong¹, Wenhai Huang¹, Yongzhou Hu¹*¹

1 Zhejiang University - École Normale Supérieure Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China, 2 Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China

Abstract

Background: Development of small-molecule inhibitors targeting phosphoinositide 3-kinase (PI3K) has been an appealing strategy for the treatment of various types of cancers.

Methodology/Principal Finding: Our approach was to perform structural modification and optimization based on previously identified morpholinoquinoxaline derivative WR1 and piperidinylquinoxaline derivative WR23 with a total of forty-five novel piperazinylquinoxaline derivatives synthesized. Most target compounds showed low micromolar to nanomolar antiproliferative potency against five human cancer cell lines using MTT method. Selected compounds showed potent PI3Kα inhibitory activity in a competitive fluorescent polarization assay, such as compound 22 (IC₅₀ 40 nM) and 41 (IC₅₀ 24 nM), which induced apoptosis in PC3 cells. Molecular docking analysis was performed to explore possible binding modes between target compounds and PI3K.

Conclusions/Significance: The identified novel piperazinylquinoxaline derivatives that showed potent PI3Kα inhibitory activity and cellular antiproliferative potency may be promising agents for potential applications in cancer treatment.

Citation: Wu P, Su Y, Guan X, Liu X, Zhang J, et al. (2012) Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors. PLoS ONE 7(8): e43171. doi:10.1371/journal.pone.0043171

Introduction

The phosphoinositide 3-kinase (PI3K) family includes lipid kinases that catalyze the phosphorylation of the 3'-hydroxyl group of phosphatidylinositol to generate second messengers, such as phosphatidylinositol-3,4,5- triphosphate (PIP₃) [1,2]. PIP₃ recruits downstream effectors along the PI3K/protein kinase B (PKB or Akt)/mammalian target of rapamycin (mTOR) signaling cascade that is of crucial importance for the regulation of cellular growth, survival, and proliferation [3]. Based on sequence homology and substrate preference, PI3Ks are divided into three classes. Class I PI3Ks are subdivided into four isoforms, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, according to different activation mechanism and varied catalytic and regulatory subunits [4]. Many studies have demonstrated that gain-of-function mutations in the gene encoding the catalytic subunit of PI3Kα, PI3CA, amplification of PI3CA, and loss-of-function mutations in PTEN, a lipid phosphatase that dephosphorylates PIP₃, result in constitutive activation of the PI3K signaling cascade, which contributes to tumor growth and progression [5,6,7]. These observations make targeting PI3Ks, especially PI3Kα, with small-molecule inhibitors a promising strategy for cancer therapy [0,9,10,11].

Considerable efforts have been devoted toward the development of small-molecule inhibitors targeting PI3K with more than twenty promising molecules have been progressed into various stages of clinical trials [11,12].

In our efforts to identify novel inhibitors of PI3K [13], we established a pharmacophore model based on reported PI3K inhibitors and identified the morpholinoquinoxaline derivative WR1 (1) as an initial hit with good potency against PI3Kα ([IC₅₀ 0.44 μM] [14], which is equivalent to that of the extensively studied tool compound LY294002 (2, PI3Kα, IC₅₀ 0.63 μM) (Fig. 1) [15,16]. Following modification based on WR1 led to the discovery of a series of piperidinylquinoxaline derivatives with good to potent PI3Kα inhibitory activity and cellular antiproliferative activity, such as WR23 (3, PI3Kα, IC₅₀ 0.025 μM) (Fig. 1) [17]. In this paper, we describe our ongoing efforts in this field that led to the identification of this series of novel piperazinylquinoxaline derivatives as potent PI3Kα inhibitors.

Among compounds synthesized based on modifying the 4-morpholino group at the 2-position of the quinoxaline scaffold of WR1, compounds 4–8 with a 4-carbamoylpyiperdin-1-yl group at the 2-position of the quinoxaline were identified as interesting leads for further study due to their potent in vitro antiproliferative activity that was equivalent to that of WR23.
Thus, compounds 4–8 were chosen for further optimization. Reversion of the carboxamide group at the 4-position of the piperidinyl ring of 4–8 led to compounds 9–13 with a 4-acetylpiperazin-1-yl group. To fully assess the impact of different piperidinyl substituents on cellular and enzymatic potency, modification in the following facets were made. Firstly, replacement of the 4-acetyl group on the piperazinyl ring with a smaller group, i.e. methyl, led to compounds 14–18. Removing the 4-methyl group and relocating the 4-methyl group as a 3-methyl group on the piperazinyl ring led to compounds 19–23 and 24–28, respectively. Secondly, replacement of the 4-acetyl group of 9–13 with a benzoyl or 4-chlorobenzoyl group afforded compounds 29–33 and 34–38, respectively, with a larger substituted piperazinyl group than that of 9–13. Thirdly, replacement of the 4-acetyl group of 9–13 with a methylsulfonyl or 4-methylphenylsulfonyl group led to compounds 39–43 and 44–48, respectively. Lastly, different from above rigid substituted piperazinyl group, a flexible 4-(3-morpholinopropyl)piperazine group of 9–13 with a methylsulfonyl group showed decreased potency than compounds 9–13 with a 4-(4-chlorobenzoyl)piperazin-1-yl group. For example, compound 14 showed increased IC50 values of 4.42, 3.89, 10.35, 4.30, and 6.15 μM against KB cell, respectively, which were equivalent to that of compounds 4–8 with a 4-(3-morpholinopropyl)piperazine group and compounds 9–13 showed IC50 values of 1.68, 0.47 and 1.17 μM, respectively.

Biological Evaluation and Structure-Activity Relationships (SAR)

Antiproliferative activity against human cancer cell lines. All synthesized target compounds were firstly tested for their antiproliferative activity against five human cancer cell lines, PC3, A549, HCT116, HL60, and KB, using MTT assay. Compounds WR1 and LY294002 were used as positive controls. As shown in Table 1, 2, 3, both piperidinylquinoxalines 4–8 and piperazinylquinoxalines 9–53 exhibited significantly improved antiproliferative activity against most tested cell lines than that of WR1 and LY294002, for example, compounds 4–8 showed IC50 ranging from 1.17 to 4.36 μM against PC3 cell, compounds 14–18 showed IC50 ranging from 0.84 to 3.09 μM against PC3 cell, while the corresponding IC50 values for WR1 and LY294002 were 18.88 and 61.35 μM, respectively. Some of the most potent compounds showed nanomolar antiproliferative activity against certain cancer cell lines, such as compound 22 and 25, which showed IC50 values of 100 and 90 nM against HL60, respectively. Reversion of the 4-carboxamoylpiperidin-1-yl group of compounds 4–8 into a 4-acetylpiperazin-1-yl group resulted in compounds 9–10 with retained inhibitory potency against tested cell lines (Table 2). For instance, compounds 9–10 showed IC50 values of 4.42, 3.89, 10.35, 4.30, and 6.15 μM against KB cell, respectively, which were equivalent to that of compounds 4–8 (KB, IC50 values of 13.73, 11.85, 10.23, 4.22 and 6.45 μM, respectively).

As shown in Table 3, compound 19 inhibited A549 with IC50 value of 1.84 μM, which showed increased IC50 values of 42.36 and 25.38 μM against HCT116, respectively.

Comparison of cytotoxic data in Table 2 and 3 also revealed that compounds 29–33 with a 4-benzoylpiperazin-1-yl group and compounds 34–38 with a 4-(4-chlorobenzoyl)piperazin-1-yl group showed decreased potency than compounds 9–13 with a 4-acetylpiperazin-1-yl group. For example, compound 9 showed an IC50 value of 1.84 μM against HCT116, while compounds 29 and 34 showed IC50 values of 42.36 and 25.38 μM, respectively, against HCT116. Similarly, compounds 44–48 with a 4-(methylphenylsulfonyl)piperazin-1-yl group showed decreased potency than compounds 9–13 with a 4-(methylsulfonyl)piperazin-1-yl group. For example, compound 43 inhibited A549 with IC50 value of 1.84 μM.

Results and Discussion

Chemical Synthesis

As shown in Figure 3, piperidinylquinoxalines 4–8 were obtained by a microwave-assisted reaction of N-carbamoylpiperazine 54 with 2-chloro-3-arylsulfonylquinazolines 55–59. 2-Chloro-3-arylsulfonylquinazolines 55–59 were synthesized using the same materials and procedures as reported [13]. As shown in Figure 4, the synthesis of piperazinylquinoxalines 9–53, similar materials and procedures were applied as synthesis of compounds 4–8 except for the use of compounds 60–67 and 70 instead of N-carbamoylpiperazine. Intermediates 63–67 were prepared using reported procedure [18,19]. N-3-(morpholinopropyl)piperazine (70) was prepared by a reaction of piperazine with 4-(3-chloropropy)morpholine (69), which was obtained by a reaction of morpholine with 1-bromo-3-chloropropane (20).

Fifty new derivatives including forty-five piperazinylquinoxalines were synthesized. Their purities were above 95% indicated by HPLC.

Figure 1. Morpholinoquinoxaline WR1, piperidinylquinoxaline WR23, and LY294002.
doi:10.1371/journal.pone.0043171.g001
an IC$_{50}$ value of 1.26 µM, while compound 48 inhibited A549 with an IC$_{50}$ value of 48.23 µM. These results indicated that an aryl substituent on the 4-piperaziny-1-yl group at the 2-position of the quinoxaline scaffold was unfavorable for antiproliferative activity.

Besides, compounds with a long flexible (4-(3-morpholinopropyl)piperazin-1-yl group (49–53) showed potent low micromolar to nanomolar antiproliferative activity against three tested cancer cell lines. For instance, the tested IC$_{50}$ values of compound 52 against PC3, A549 and HCT116 were 1.19, 0.34 and 0.22 µM, respectively.

**Inhibition of PI3Kα.** Selected compounds were then tested for their enzymatic inhibitory activity against PI3Kα using a competitive fluorescence polarization (FP) assay to determine the molecular target of synthesized compounds [21]. As shown in Table 4, compound 4 with a 4-carbamoylpiperidin-1-yl group did not show significant inhibitory activity against PI3Kα (IC$_{50}$ value >10 µM). Most tested piperazinylquinoxaline derivatives
showed comparable PI3Kα inhibitory activity with that of WR1 and LY294002. The most potent compounds 2-(piperazin-1-yl)-3-(4-bromophenylsulfonyl)quinoxaline 22 (IC\textsubscript{50}: 40 nM) and 2-(4-methylsulfonyl)piperazin-1-yl-3-(4-methoxyphenylsulfonyl)quinoxaline 41 (IC\textsubscript{50}: 24 nM) showed nanomolar inhibitory activity against PI3Kα. Consistent with the result of antiproliferative test, compound 29 with a 4-benzoylpiperazin-1-yl group (IC\textsubscript{50}: >10 μM) and compound 44 with a 4-(4-methylphenoxy)sulfonyl)piperazin-1-yl group (IC\textsubscript{50}: >10 μM) showed less potent PI3Kα inhibitory activity than that of compound 24 with a 3-methylpiperazin-1-yl group (IC\textsubscript{50}: 0.059 μM) and compound 39 with a 4-(methylsulfonyl)piperazin-1-yl group (IC\textsubscript{50}: 1.34 μM). The values of binding efficiency index (BEI), a modified ligand efficiency index based on a molecular weight (MW) scale [22], were calculated for target compounds that exhibited good to potent PI3Kα inhibitory activity to evaluate binding efficiency of these compounds. As shown in Table 5, although most compounds showed BEI values comparable to that of WR1, LY294002 or WR23, no significant improvement in ligand binding efficiency was observed. This analysis based on BEI indicated that further modification with an aim to improve ligand binding efficiency might expedite the optimization process for this series of compounds.

Apoptosis assay. Piperazinylquinoxaline derivative 41 was further tested for its ability to induce apoptosis in PC3 cells. GDC0941, one of the most advanced PI3K inhibitors revealed so far, was used as the positive control [23] (Fig. 5). With an apoptotic percent of 1.71% of the control, the percent of apoptotic PC3 cells induced by compound 41 and GDC0941 in 5 μM after treatment of 24 h were 4.48% and 3.12%, respectively. The fact that compound 41 showed an apoptotic percent of 32.83% in 10 μM, in comparison with that of 5.85 for GDC0941, indicated the potent apoptosis inductive activity of compound 41.

Cell cycle arrest. Moreover, flow cytometric analysis was performed to determine whether target compounds could induce cell cycle arrest in PC3 cells. GDC0941 was used as the positive control. PC3 cells were treated with compound 41 and GDC0941 in two different concentrations (2 and 4 μM) for 24 h, the results are presented as Figure 6. GDC0941 induced cell cycle arrest in G1 phase with a simultaneous decrease of cells in S phase. Compound 41 showed similar trend while the percent of cell in G1 phase was smaller.

Molecular Docking Analysis

Compounds 41 and 22 that showed the most potent inhibitory activity against PI3Kα were subjected to molecular docking analysis to investigate possible binding mode between target compounds and PI3Kα. Co-crystal structures of mutant PI3Kα with small-molecule inhibitor (PDB ID: 3HHM) was utilized as the template to perform docking analysis [24]. Based on the docking results as shown in Figure 7, compound 41 might form three hydrogen bond interactions with PI3Kα, the methoxy oxygen with the NH of Val851 (distance: 2.1 Å), one of the methylsulfonyl oxygen with the OH of Ser774 (distance: 1.9 Å), and one of the quinoxaline nitrogen with the NHo of Lys802 (distance 2.4 Å) (Fig. 7A); the hydrogen bond interaction with Val851 is probably retained in the PI3Kα-22 docking complex (Fig. 7B). Although both 41 and 22 have the potential to interact with Val851 through the formation of a hydrogen bond interaction that is believed to be of significant importance for PI3K inhibition [25], 41 and 22 tend to bind with PI3Kα in different modes, the quinoxaline moiety of 41 might bind with an affinity pocket close to Lys802 and its methylsulfonylpiperazinyl moiety extends to the solvent front (Fig. 7C), while the quinoxaline moiety of 22 might extend to the solvent front with its bromophenylsulfonyl moiety binds with the affinity pocket (Fig. 7D).

Conclusions

Series of novel piperazinylquinixaline derivatives have been identified as PI3Kα inhibitors in this study. Representative compounds 2-(piperazin-1-yl)-3-(4-bromophenylsulfonyl)quinoxaline (22) and 2-(4-(methylsulfonyl)piperazin-1-yl)-3-(4-methoxyphenylsulfonyl)quinoxaline (41) exhibit low micromolar to nanomolar antiproliferative potency against human cell lines and inhibit PI3Kα with IC\textsubscript{50} values of 40 and 24 nM, respectively. Compound 41 potently induces apoptosis and appears to have certain effort on cell cycle arrest in G1 phase. Molecular docking analysis shows the possible binding modes between 41 and PI3Kα. Our data hold promise for the development of piperazinylquinixaline derivatives as PI3Kα inhibitors for cancer therapy.

Materials and Methods

Experimental Methods

Reagents and apparatus. Melting points were determined with a B-540 Buchi apparatus and are uncorrected. NMR spectra were recorded on a Bruker 500 (500 MHz) spectrometer at room temperature (chemical shifts are reported in ppm (δ) using TMS as
Figure 4. Synthesis of piperazinylquinoxalines 9–53.
doi:10.1371/journal.pone.0043171.g004

a. isopropanol, microwave irradiation, 80°C;
b. acetyl chloride (for 9-13)/ benzyol chloride (for 29-33)/ 4-chlorobenzoyl chloride (for 34-38), acetic acid;
c. methanesulfonyl chloride (for 39-43)/ 4-methylbenzene-1-sulfonyl chloride (for 44-48), acetic acid;
d. 1-bromo-3-chloropropane, DMF, NaH;
e. piperazine, isopropanol, microwave irradiation, 150°C.
Table 1. Antiproliferative activity of piperazinylquinolines (4–8).

| Cpd. | 2-substituent on quinoline | IC_{50} (µM)* |
|------|---------------------------|--------------|
| 4    | 4-carbamoylpiperidin-1-yl | 1.20         |
| 5    | 4-carbamoylpiperidin-1-yl | 2.28         |
| 6    | 4-carbamoylpiperidin-1-yl | 2.83         |
| 7    | 4-carbamoylpiperidin-1-yl | 1.17         |
| 8    | 4-carbamoylpiperidin-1-yl | 4.36         |
| WR1  | morpholino                | 18.88        |
| LY294002 | –                | 61.35       |

IC_{50} (µM)*

*The mean value of at least two separate determinations.

Table 2. Antiproliferative activity of piperazinylquinolines (9–13).

| Cpd. | 2-substituent on quinoline | IC_{50} (µM)* |
|------|---------------------------|--------------|
| 9    | 4-acetypiperazin-1-yl     | 2.25         |
| 10   | 4-acetypiperazin-1-yl     | 2.27         |
| 11   | 4-acetypiperazin-1-yl     | 2.18         |
| 12   | 4-acetypiperazin-1-yl     | 3.03         |
| 13   | 4-acetypiperazin-1-yl     | 3.17         |
| WR1  | morpholino                | 18.88        |
| LY294002 | –                | 61.35       |

IC_{50} (µM)*

*The mean value of at least two separate determinations.

General procedure for the synthesis of 4–8 (procedure A). To a microwave vial (2–5 mL) were added 2-chloro-3-(acetyl)sulfonyl)quinoline 55–59 (0.1 mmol), N-carbamoylpiperidine (0.5 mmol), and isopropl alcohol (2 mL). The sealed vial was heated at 80°C for 10 min by microwave irradiation in a Biotage™ Initiator Synthesizer using a fixed hold time. The mixture was then cooled to room temperature and the residue obtained after evaporation under vacuum was subjected to purification over silica gel chromatography eluting with PE:EtOAc:CHCl₃ (4:1, v/v) to afford target compounds as yellow solid.

2- (4-Carbamoylpiperidin-1-yl)-3-(phenylsulfonyl)quinoline 4. Yield: 64%; mp: 170–174°C. ¹H NMR (500 MHz, CDCl₃): δ 8.00 (d, 2H, J = 7.5 Hz, aromatic H), 7.77 (d, 1H, J = 8.5 Hz, aromatic H), 7.69-7.62 (m, 3H, aromatic H), 7.55 (t, 2H, J = 8.0 Hz, aromatic H), 7.47 (t, 1H, J = 7.5 Hz, aromatic H), 5.59 (brs, 1H, NH₂), 5.40 (brs, 1H, NH₂), 4.36 (d, 2H, J = 13.0 Hz, piperidine H), 3.20 (dt, 2H, J = 13.0 and 3.0 Hz, piperidine H), 2.51-2.45 (m, 1H, piperidine H), 2.11-2.04 (m, 4H, piperidine H), ESI-MS (m/z): 397 [M+H]+.

2- (4-Carbamoylpiperidin-1-yl)-3-(4-methylphenylsulfonyl)quinoline 5. Yield: 53%; mp: 200–203°C. ¹H NMR (500 MHz, CDCl₃): δ 7.88 (d, 2H, J = 8.0 Hz, aromatic H), 7.76 (d, 1H, J = 8.5 Hz, aromatic H), 7.69-7.65 (m, 2H, aromatic H), 7.46 (t, 1H, J = 8.5 Hz, aromatic H), 7.32 (d, 2H, J = 8.0 Hz, aromatic H), 5.70 (brs, 2H, NH₂), 4.34 (d, 2H, J = 13.0 Hz, piperidine H), 3.17 (dt, 2H, J = 13.0 and 3.0 Hz, piperidine H), 2.48-2.42 (m, 4H, piperidine H and CH₃), 2.08-2.02 (m, 4H, piperidine H), ESI-MS (m/z): 411 [M+H]+.

2- (4-Carbamoylpiperidin-1-yl)-3-(4-methoxyphenylsulfonyl)quinoline 6. Yield: 42%; mp: 185–187°C. ¹H NMR (500 MHz, CDCl₃): δ 7.94 (d, 2H, J = 8.5 Hz, aromatic H), 7.76 (d, 1H, J = 8.0 Hz, aromatic H), 7.70-7.65 (m, 2H, aromatic H), 7.47 (t, 1H, J = 7.5 Hz, aromatic H), 7.00 (d, 2H, J = 8.5 Hz, aromatic H), 5.60 (brs, 1H, NH₂), 5.39 (brs, 1H, NH₂), 4.36 (d, 2H, J = 13.0 Hz, piperidine H), 3.88 (s, 3H, OCH₃), 3.18 (dt, 2H, J = 13.0 and 3.0 Hz, piperidine H), 2.49-2.46 (m, 1H, piperidine H), 2.10-2.05 (m, 4H, piperidine H), ESI-MS (m/z): 477 [M+H]+.

2- (4-Carbamoylpiperidin-1-yl)-3-(4-bromomethylsulfonyl)quinoline 7. Yield: 61%; mp: 209–210°C. ¹H NMR (500 MHz, CDCl₃): δ 7.94 (d, 1H, J = 9.0 Hz, aromatic H), 7.86 (d, 1H, J = 8.0 Hz, aromatic H), 7.77-7.75 (m, 1H, aromatic H), 7.70-7.64 (m, 3H, aromatic H), 7.48-7.45 (m, 1H, aromatic H), 7.00 (d, 1H, J = 9.0 Hz, aromatic H), 5.60 (brs, 1H, NH₂), 5.43 (brs, 1H, NH₂), 4.37 (d, 2H, J = 13.0 Hz, piperidine H), 3.21-3.16 (m, 2H, piperidine H), 2.49-2.45 (m, 1H, piperidine H), 2.11-2.05 (m, 4H, piperidine H), ESI-MS (m/z): 477 [M+H]+.

2- (4-Carbamoylpiperidin-1-yl)-3-(4-fluoromethylsulfonyl)quinoline 8. Yield: 68%; mp: 198–202°C. ¹H NMR (500 MHz, CDCl₃): δ 8.03 (d, 2H, J = 8.5 Hz, aromatic H), 7.77 (d, 1H, J = 8.5 Hz, aromatic H), 7.64 (d, 1H, J = 7.5 Hz, aromatic H), 7.47 (dt, 1H, J = 8.0 and 1.0 Hz, aromatic H), 7.23 (t, 2H, J = 8.0 Hz, aromatic H), 5.60 (brs, 1H, NH₂), 5.47 (brs, 1H, NH₂), 4.38 (d, 2H, J = 13.0 Hz, piperidine H), 3.21 (dt, 2H, J = 13.0 and 3.0 Hz, piperidine H), 2.50-2.45 (m, 1H, piperidine H), 2.11-2.04 (m, 4H, piperidine H), ESI-MS (m/z): 415 [M+H]+.

General procedure for the synthesis of 9–13. Similar with procedure A, but N-carbamoylpiperazine was replaced by N-acetyl piperazine. Target compounds were obtained as yellow solid.

2- (4-Acetylpiperazin-1-yl)-3-(phenylsulfonyl)quinoline 9. Yield: 38%; mp: 144–146°C. ¹H NMR (500 MHz, CDCl₃): δ 8.01-8.00 (m, 2H, aromatic H), 7.81-7.79 (m, 1H, aromatic H), 7.71-7.67 (m, 3H, aromatic H), 7.55 (m, 2H, aromatic H), 7.50 (m, 1H, aromatic H), 3.89 (m, 2H, piperidine H), 3.76-3.71 (m, 4H, piperidine H), 3.67 (m, 2H, piperidine H), 2.18 (s, 3H, CH₃), ESI-MS (m/z): 397 [M+H]+.

2- (4-Acetylpiperazin-1-yl)-3-(4-methylphenylsulfonyl)quinoline 10. Yield: 36%; mp: 148–150°C. ¹H NMR (500 MHz, CDCl₃): δ 7.89 (d, 2H, J = 8.0 Hz, aromatic H), 7.80 (d, 1H, J = 8.0 Hz, aromatic H), 7.72 (t, 2H, J = 7.5 Hz, aromatic H).
Table 3. Antiproliferative activity of piperazinylquinoxalines (14–53).

| Cpd. | 2-substituent on quinoxaline | IC₅₀ (µM)ᵃ | PC3 | A549 | HCT116 | HL60 | KB |
|------|-----------------------------|------------|-----|------|--------|------|----|
| 14   | 4-methylpiperazin-1-yl       | 2.94       | 14.03| 2.78 | 0.77   | 4.54 |
| 15   | 4-methylpiperazin-1-yl       | 0.84       | 2.4  | 1.68 | 0.69   | 0.47 |
| 16   | 4-methylpiperazin-1-yl       | 1.55       | 8.57 | 2.37 | 0.54   | 2.53 |
| 17   | 4-methylpiperazin-1-yl       | 1.01       | 5.18 | 2.31 | 0.28   | 0.87 |
| 18   | 4-methylpiperazin-1-yl       | 3.09       | 7.95 | 8.21 | 2.75   | 21.64|
| 19   | piperazin-1-yl               | 0.90       | 12.82| 0.99 | 0.11   | 8.27 |
| 20   | piperazin-1-yl               | 1.32       | 14.39| 0.47 | 0.12   | 7.26 |
| 21   | piperazin-1-yl               | 0.68       | 1.37 | 0.63 | 0.16   | 11.48|
| 22   | piperazin-1-yl               | 0.36       | 0.75 | 0.19 | 0.10   | 9.89 |
| 23   | piperazin-1-yl               | 2.05       | 2.79 | 2.43 | 1.39   | 4.58 |
| 24   | 3-methylpiperazin-1-yl       | 1.44       | 1.36 | 0.68 | 0.15   | 8.73 |
| 25   | 3-methylpiperazin-1-yl       | 2.03       | 1.60 | 1.17 | 0.09   | 9.18 |
| 26   | 3-methylpiperazin-1-yl       | 0.93       | 1.65 | 0.54 | 0.16   | 8.53 |
| 27   | 3-methylpiperazin-1-yl       | 0.60       | 0.57 | 0.32 | 0.12   | 9.46 |
| 28   | 3-methylpiperazin-1-yl       | 2.34       | 3.45 | 2.20 | 1.95   | 2.03 |
| 29   | 4-benzoylpiperazin-1-yl      | 4.99       | 5.20 | 42.36| 7.20   | 1.22 |
| 30   | 4-benzoylpiperazin-1-yl      | 5.81       | 8.03 | 6.90 | 17.28  | 3.67 |
| 31   | 4-benzoylpiperazin-1-yl      | 3.63       | 7.43 | 17.24| 6.93   | 5.65 |
| 32   | 4-benzoylpiperazin-1-yl      | 1.40       | 3.96 | 10.08| 17.37  | 3.37 |
| 33   | 4-benzoylpiperazin-1-yl      | 1.77       | 1.16 | 8.88 | 6.95   | 1.22 |
| 34   | 4-(4-chlorobenzoyl)piperazin-1-yl | 2.74 | 3.86 | 25.38| 5.84   | 0.93 |
| 35   | 4-(4-chlorobenzoyl)piperazin-1-yl | 3.61 | 21.57| 9.84 | 6.09   | 2.84 |
| 36   | 4-(4-chlorobenzoyl)piperazin-1-yl | 2.43 | >50   | 9.62 | 5.58   | 6.03 |
| 37   | 4-(4-chlorobenzoyl)piperazin-1-yl | 2.89 | >50   | 10.57| 6.11   | 5.09 |
| 38   | 4-(4-chlorobenzoyl)piperazin-1-yl | 4.05 | 17.70| 8.75 | 4.44   | 1.88 |
| 39   | 4-(4-methylsulfonyl)piperazin-1-yl | 1.07 | 2.37 | 12.1 | NTᵇ  NTᵇ |
| 40   | 4-(4-methylsulfonyl)piperazin-1-yl | 5.35 | 1.93 | 1.07 | NTᵇ  NTᵇ |
| 41   | 4-(4-methylsulfonyl)piperazin-1-yl | 2.21 | 1.32 | 0.55 | NTᵇ  NTᵇ |
| 42   | 4-(4-methylsulfonyl)piperazin-1-yl | 1.95 | 1.32 | 0.41 | NTᵇ  NTᵇ |
| 43   | 4-(4-methylsulfonyl)piperazin-1-yl | 3.30 | 1.26 | 0.33 | NTᵇ  NTᵇ |
| 44   | 4-tosylpiperazin-1-yl        | 2.19       | 24.26| 7.49 | 6.40   | 3.08 |
| 45   | 4-tosylpiperazin-1-yl        | 3.48       | 49.47| 1.92 | 9.28   | 2.68 |
| 46   | 4-tosylpiperazin-1-yl        | 6.20       | >50  | 14.22| 14.95  | 2.35 |
| 47   | 4-tosylpiperazin-1-yl        | 4.89       | 19.51| 5.07 | 10.27  | 2.73 |
| 48   | 4-tosylpiperazin-1-yl        | 3.39       | 48.23| 3.76 | 9.48   | 5.17 |
| 49   | 4-(3-morpholinopropyl)piperazin-1-yl | 5.12 | 0.73 | 0.65 | NTᵇ  NTᵇ |
| 50   | 4-(3-morpholinopropyl)piperazin-1-yl | 3.83 | 0.51 | 0.31 | NTᵇ  NTᵇ |
| 51   | 4-(3-morpholinopropyl)piperazin-1-yl | 9.30 | 2.10 | 2.59 | NTᵇ  NTᵇ |

ᵃThe mean value of at least two separate determinations.
ᵇNT: not tested.

Table 3. Cont.

| Cpd. | 2-substituent on quinoxaline | IC₅₀ (µM)ᵃ | PC3 | A549 | HCT116 | HL60 | KB |
|------|-----------------------------|------------|-----|------|--------|------|----|
| 52   | 4-(3-morpholinopropyl)piperazin-1-yl | 1.19 | 0.34 | 0.22 | NTᵇ  NTᵇ |
| 53   | 4-(3-morpholinopropyl)piperazin-1-yl | 4.80 | 1.12 | 0.93 | NTᵇ  NTᵇ |
| 54   | 2-(4-Chloroquipazine-1-yl) | 61.35 | 89.65 | 56.01 | 9.94 | 44.76 |

General procedure for the synthesis of 14–18. Similar with procedure A, but N-carbamoylpiperazine was replaced by N-methylpiperazine. Target compounds were obtained as yellow solid.

2-(4-Methylpiperezin-1-yl)-3-(phenylsulfonyl)quinoxaline 14. Yield: 74%; mp: 154–157°C. 1H NMR (500 MHz, CDCl₃): 7.80–7.51 (m, 4H, aromatic H), 7.74–7.67 (m, 4H, aromatic H), 7.64–7.42 (m, 4H, aromatic H), 7.38–7.16 (m, 4H, aromatic H), 7.12–6.83 (m, 4H, aromatic H), 6.75–6.43 (m, 4H, aromatic H), 5.61–5.33 (m, 4H, aromatic H), 3.90–3.65 (m, 4H, aromatic H), 3.85–3.60 (m, 4H, aromatic H), 3.43–3.20 (m, 4H, aromatic H), 3.13–2.85 (m, 4H, aromatic H), 2.85–2.50 (m, 4H, aromatic H), 2.45–2.15 (m, 4H, aromatic H), 2.15–1.85 (m, 4H, aromatic H), 1.85–1.55 (m, 4H, aromatic H), 1.55–1.25 (m, 4H, aromatic H), 1.25–0.95 (m, 4H, aromatic H), 0.95–0.65 (m, 4H, aromatic H), 0.65–0.35 (m, 4H, aromatic H), 0.35–0.05 (m, 4H, aromatic H), 0.05–0.00 (m, 4H, aromatic H). ESI-MS (m/z): [M+H]+ 427 (100%), [M+Na]+ 449 (100%).
Table 4. PI3Kα inhibitory activity of target compounds.

| Cpd. | 2-substituent on quinoxaline scaffold | 4-substituent of phenylsulfonfyl moiety | IC_{50} (μM)* |
|------|--------------------------------------|----------------------------------------|---------------|
| 4    | 4-carbamoylpiperidin-1-yl            | H                                      | >10           |
| 9    | 4-acycloxyphenylpiperazin-1-yl       | H                                      | 1.087         |
| 14   | 4-methylpiperazin-1-yl              | H                                      | >10           |
| 15   | 4-methylpiperazin-1-yl              | methyl                                 | >10           |
| 17   | 4-methylpiperazin-1-yl              | bromo                                  | 4.25          |
| 19   | 4-methylpiperazin-1-yl              | H                                      | 0.19          |
| 22   | 4-piperazin-1-yl                    | bromo                                  | 0.04          |
| 24   | 4-methylpiperazin-1-yl              | H                                      | 0.059         |
| 25   | 4-methylpiperazin-1-yl              | methyl                                 | 0.65          |
| 26   | 4-methylpiperazin-1-yl              | methoxy                                | 0.24          |
| 27   | 4-methylpiperazin-1-yl              | bromo                                  | 0.061         |
| 29   | 4-piperazin-1-yl                    | H                                      | >10           |
| 34   | 4-(4-methylbenzoyl)piperazin-1-yl    | H                                      | 2.75          |
| 39   | 4-(4-chlorobenzoyl)piperazin-1-yl    | H                                      | 1.34          |
| 40   | 4-(4-methylbenzoyl)piperazin-1-yl    | methyl                                 | 0.46          |
| 41   | 4-(4-methylbenzoyl)piperazin-1-yl    | methoxy                                | 0.024         |
| 42   | 4-(4-methylbenzoyl)piperazin-1-yl    | bromo                                  | 0.44          |
| 43   | 4-(4-methylbenzoyl)piperazin-1-yl    | fluoro                                 | 1.012         |
| 49   | 4-(4-bromobenzyloxy)piperazin-1-yl  | H                                      | >10           |
| 52   | 4-(4-bromobenzyloxy)piperazin-1-yl  | bromo                                  | 0.20          |
| WR1c | morpholino                          | H                                      | 0.44          |
| LY294002d | –                              | –                                      | 0.63          |

*The mean value of at least two separate determinations.

1NT: not tested.

1Reported value, ref. 16.

1Reported value, ref. 10.

doi:10.1371/journal.pone.0043171.t004

Piperazinylquinoxalines as PI3K Inhibitors

General procedure for the synthesis of 19–23. Similar with procedure A, but N-carbamoylpyrrole was replaced by piperazine.

2-(Piperazin-1-yl)-3-(4-fluorophenylsulfonyl)quinazoline 19. Yellow mucous substance. Yield: 64%; 1H NMR (500 MHz, CDCl₃): δ 8.00 (d, 2H, J = 8.0 Hz, aromatic H), 7.79 (d, 1H, J = 9.0 Hz, aromatic H), 7.69-7.62 (m, 3H, aromatic H, 3.89 (s, 3H, aromatic OCH₃), 3.81 (t, 4H, J = 4.5 Hz, piperidine H), 2.75 (t, 4H, J = 4.5 Hz, piperidine H), 2.43 (s, 3H, piperidine CH₃). ESI-MS (m/z): 387 [M+H]⁺.

2-(Methylpiperazin-1-yl) -3- (4-bromophenylsulfonyl)quinazoline 20. Orange mucous substance. Yield: 73%; 1H NMR (500 MHz, CDCl₃): δ 8.00 (d, 2H, J = 8.0 Hz, aromatic H), 7.79 (d, 1H, J = 9.0 Hz, aromatic H), 7.69-7.62 (m, 3H, aromatic H, 3.89 (s, 3H, aromatic OCH₃), 3.81 (t, 4H, J = 4.5 Hz, piperidine H), 2.75 (t, 4H, J = 4.5 Hz, piperidine H), 2.43 (s, 3H, piperidine CH₃). ESI-MS (m/z): 449 [M+H]⁺.


Table 5. Binding efficiency index (BEI) of selected target compounds.

| Cpd. | calculated MW (kDa) | IC₅₀ (M) | BEI* |
|------|---------------------|---------|------|
| 9    | 0.396               | 0.000001087 | 15.1 |
| 17   | 0.448               | 0.00000425  | 12.0 |
| 19   | 0.354               | 0.00000019  | 19.0 |
| 22   | 0.434               | 0.00000004  | 17.0 |
| 24   | 0.368               | 0.00000059  | 19.7 |
| 25   | 0.382               | 0.00000065  | 16.2 |
| 26   | 0.398               | 0.00000024  | 16.6 |
| 27   | 0.448               | 0.00000061  | 16.1 |
| 34   | 0.492               | 0.00000275  | 11.3 |
| 39   | 0.432               | 0.00000134  | 13.6 |
| 40   | 0.466               | 0.00000046  | 13.6 |
| 41   | 0.462               | 0.00000024  | 16.5 |
| 42   | 0.512               | 0.00000044  | 12.4 |
| 43   | 0.450               | 0.00000112  | 13.3 |
| 49   | 0.481               | 0.00000018  | 14.0 |
| 52   | 0.561               | 0.00000020  | 11.9 |
| WR1  | 0.355               | 0.00000044  | 17.9 |
| LY294002 | 0.307        | 0.00000063  | 20.2 |
| WR23 | 0.448               | 0.00000025  | 17.0 |

*Binding efficiency index (BEI) = pIC₅₀ (M)/MW (kDa).

doi:10.1371/journal.pone.0043171.t005

Figure 5. Apoptosis induction of compound 41 and GDC0941 in PC3 cells. After treatment with 41 and GDC0941 (5 or 10 μM) for 24 h, PC3 cells were harvested and detected of apoptosis by flow cytometry using PI apoptosis detection kit. Vertical axes stand for the counts of relative number of PC3 cells; horizontal axes stand for the relative fluorescence light intensity measured as pulse-area (FL2-A).

doi:10.1371/journal.pone.0043171.g005

2-(Piperazin-1-yl)-3-(4-bromophenylsulfonyl)quinoxaline 22.
Yellow solid. Yield: 90%; mp: 92–96°C. ¹H NMR (500 MHz, CDCl₃): δ 7.94 (d, 2H, J = 8.5 Hz, aromatic H), 7.79 (d, 1H, J = 8.5 Hz, aromatic H), 7.72-7.65 (m, 4H, aromatic H), 7.50 (t, 1H, J = 8.0 Hz, aromatic H), 3.81 (t, 4H, J = 4.5 Hz, piperidine H), 3.25 (t, 4H, J = 4.5 Hz, piperidine H). ESI-MS (m/z): 385 [M+1]⁺.

2-(Piperazin-1-yl)-3-(4-fluorophenylsulfonyl)quinoxaline 23.
Orange-yellow mucous substance. Yield: 81%; ¹H NMR (500 MHz, CDCl₃): δ 8.04 (d, 2H, J = 9.0 Hz, aromatic H), 7.79 (d, 1H, J = 8.5 Hz, aromatic H), 7.71 (dt, 1H, J = 8.0 and 1.0 Hz, aromatic H), 7.65 (d, 1H, J = 8.0 Hz, aromatic H), 7.49 (dt, 2H, J = 8.0 and 1.0 Hz, aromatic H), 7.49 (t, 2H, J = 8.5 Hz, aromatic H), 3.82 (t, 4H, J = 4.5 Hz, piperidine H), 3.28 (t, 4H, J = 4.5 Hz, piperidine H). ESI-MS (m/z): 373 [M+1]⁺.

General procedure for the synthesis of 24–28. Similar with procedure A, but N-carbamoylpiperazine was replaced by 2-methylpiperazine.

2-(3-Methylpiperazin-1-yl)-3-(phenylsulfonyl)quinoxaline 24.
Orange-yellow mucous substance. Yield: 91%; ¹H NMR (500 MHz, CDCl₃): δ 7.99 (d, 2H, J = 8.5 Hz, aromatic H), 7.76 (d, 1H, J = 8.5 Hz, aromatic H), 7.71 (dt, 1H, J = 8.0 and 1.5 Hz, aromatic H), 7.53 (t, 2H, J = 8.0 Hz, aromatic H), 7.44 (dt, 1H, J = 8.0 and 1.5 Hz, aromatic H), 4.24 (dt, 2H, J = 11.0 and 2.0 Hz, piperidine H), 3.22-3.16 (m, 4H, piperidine H), 2.84-2.80 (m, 1H, piperidine H), 1.19 (d, 3H, J = 6.0 Hz, piperidine CH₃). ESI-MS (m/z): 369 [M+1]⁺.

2-(3-Methylpiperazin-1-yl)-3-(4-methylphenylsulfonyl)quinoxaline 25.
Yellow solid. Yield: 74%; mp: 136–138°C. ¹H

Table 5. Binding efficiency index (BEI) of selected target compounds.

| Cpd. | calculated MW (kDa) | IC₅₀ (M) | BEI* |
|------|---------------------|---------|------|
| 9    | 0.396               | 0.000001087 | 15.1 |
| 17   | 0.448               | 0.00000425  | 12.0 |
| 19   | 0.354               | 0.00000019  | 19.0 |
| 22   | 0.434               | 0.00000004  | 17.0 |
| 24   | 0.368               | 0.00000059  | 19.7 |
| 25   | 0.382               | 0.00000065  | 16.2 |
| 26   | 0.398               | 0.00000024  | 16.6 |
| 27   | 0.448               | 0.00000061  | 16.1 |
| 34   | 0.492               | 0.00000275  | 11.3 |
| 39   | 0.432               | 0.00000134  | 13.6 |
| 40   | 0.466               | 0.00000046  | 13.6 |
| 41   | 0.462               | 0.00000024  | 16.5 |
| 42   | 0.512               | 0.00000044  | 12.4 |
| 43   | 0.450               | 0.00000112  | 13.3 |
| 49   | 0.481               | 0.00000018  | 14.0 |
| 52   | 0.561               | 0.00000020  | 11.9 |
| WR1  | 0.355               | 0.00000044  | 17.9 |
| LY294002 | 0.307        | 0.00000063  | 20.2 |
| WR23 | 0.448               | 0.00000025  | 17.0 |

*Binding efficiency index (BEI) = pIC₅₀ (M)/MW (kDa).

doi:10.1371/journal.pone.0043171.t005

Figure 5. Apoptosis induction of compound 41 and GDC0941 in PC3 cells. After treatment with 41 and GDC0941 (5 or 10 μM) for 24 h, PC3 cells were harvested and detected of apoptosis by flow cytometry using PI apoptosis detection kit. Vertical axes stand for the counts of relative number of PC3 cells; horizontal axes stand for the relative fluorescence light intensity measured as pulse-area (FL2-A).

doi:10.1371/journal.pone.0043171.g005
NMR (500 MHz, CDCl3): \( \delta \) 7.88 (d, 2H, \( J = 8.0 \) Hz, aromatic H), 7.78 (d, 1H, \( J = 8.0 \) Hz, aromatic H), 7.69-7.66 (m, 2H, aromatic H), 7.47 (t, 1H, \( J = 8.0 \) Hz, aromatic H), 7.33 (d, 2H, \( J = 8.0 \) Hz, aromatic H), 4.24-4.22 (m, 2H, piperidine H), 3.31-3.27 (m, 4H, piperidine H), 2.96 (t, 1H, \( J = 11.0 \) Hz, piperidine H), 2.44 (s, 3H, aromatic CH3), 1.29 (d, 3H, \( J = 6.0 \) Hz, piperidine CH3). ESI-MS (m/z): 383 [M+1]+.

2-(3-Methylpiperazin-1-yl) -3- (4-methoxyphenylsulfonyl) quinoxaline 26. Yellow solid. Yield: 86%; mp: 130–133°C. 1H NMR (500 MHz, CDCl3): \( \delta \) 7.94 (d, 2H, \( J = 9.0 \) Hz, aromatic H), 7.76 (d, 1H, \( J = 8.5 \) Hz, aromatic H), 7.68-7.64 (m, aromatic H), 7.46 (dt, 1H, \( J = 8.5 \) and 1.5 Hz, aromatic H), 6.99 (d, 2H, \( J = 8.5 \) Hz, aromatic H), 4.25-4.21 (m, 2H, piperidine H), 3.87 (s, 3H, aromatic OCH3), 3.29-3.17 (m, 4H, piperidine H), 2.89-2.85 (m, 1H, piperidine H), 1.24 (d, 3H, \( J = 6.0 \) Hz, piperidine CH3). ESI-MS (m/z): 399 [M+1]+.

General procedure for the synthesis of 29–33. Similar with procedure A, but \( N \)-carbamoylpiperazine was replaced by \( N \)-benzoylpiperazine. Target compounds were obtained as yellow solid.

2- (4-Benzoylpiperazin-1-yl) -3- (4-methylphenylsulfonyl) quinoxaline 30. Yield: 35%; mp: 182–185°C. 1H NMR (500 MHz, CDCl3): \( \delta \) 7.89 (d, 2H, \( J = 8.5 \) Hz, aromatic H), 7.81 (d, 1H, \( J = 8.5 \) Hz, aromatic H), 7.52 (dt, 1H, \( J = 8.0 \) and 1.5 Hz, aromatic H), 7.48-7.44 (m, 5H, aromatic H), 4.11-4.04 (m, 2H, piperazine H), 3.84-3.65 (m, 6H, piperazine H), 2.46 (s, 3H, aromatic CH3). ESI-MS (m/z): 473 [M+1]+.
2-(4-Benzoylpiperazin-1-yl)-3-(4-methoxyphenylsulfonyl) quinoxaline 31. Yield: 63%; mp: 166–169°C. 1H NMR (500 MHz, CDCl3): δ 7.94 (d, 2H, J=9.0 Hz, aromatic H), 7.80 (d, 1H, J=8.0 Hz, aromatic H), 7.72-7.68 (t, 2H, J=8.0 Hz, aromatic H), 7.52-7.43 (m, 6H, aromatic H), 7.01-6.99 (d, 2H, J=8.5 Hz, aromatic H), 4.11-4.03 (m, 2H, piperazine H), 3.90 (s, 3H, aromatic OCH3), 3.85-3.63 (m, 6H, piperazine H). ESI-MS (m/z): 489 [M+1]+.

2-(4-Benzoylpiperazin-1-yl)-3-(4-bromophenylsulfonyl) quinoxaline 32. Yield: 50%; mp: 204–205°C. 1H NMR (500 MHz, CDCl3): δ 7.87 (d, 2H, J=8.5 Hz, aromatic H), 7.81 (d, 1H, J=8.5 Hz, aromatic H), 7.74-7.66 (m, 4H, aromatic H), 7.52 (dt, 1H, J=7.0 and 1.0 Hz, aromatic H), 7.47-7.45 (m, 5H, aromatic H), 4.12-4.05 (m, 2H, piperazine H), 3.84-3.65 (m, 6H, piperazine H). ESI-MS (m/z): 539 [M+1]+.

2-(4-Benzoylpiperazin-1-yl)-3-(4-fluorophenylsulfonyl) quinoxaline 33. Yield: 74%; mp: 200–202°C. 1H NMR (500 MHz, CDCl3): δ 8.04 (dd, 2H, J=9.0 and 5.0 Hz, aromatic H), 7.81 (d, 1H, J=8.5 Hz, aromatic H), 7.74 (dt, 1H, J=8.5 and 1.0 Hz, aromatic H), 7.67 (d, 1H, J=7.5 Hz, aromatic H), 7.53 (dt, 1H, J=8.5 and 1.0 Hz, aromatic H), 7.48-7.43 (m, 5H, aromatic H), 7.25-7.22 (t, 2H, J=8.5 Hz, aromatic H) 4.11-4.10 (m, 2H, piperazine H), 3.82-3.70 (m, 6H, piperazine H). ESI-MS (m/z): 477 [M+1]+.

Figure 7. Molecular docking of compounds 41 and 22 with PI3Ka. Compound 41 is shown in cyan backbone, compound 22 is shown in magenta backbone, and selected amino residues are shown in green backbones. (A) Cartoon show of 41 docked into the ATP binding site of PI3Ka; (B) cartoon show of 22-PI3Ka docking complex; (C) surface show of 41-PI3Ka docking complex with 41 shown in dotted stick; (D) surface show of 22-PI3Ka docking complex with 22 shown in dotted stick.

doi:10.1371/journal.pone.0043171.g007

Piperazinylquinoxalines as PI3K Inhibitors
General procedure for the synthesis of 34–38. Similar with procedure A, but N-carbamoylpiperazine was replaced by N-(4-chlorobenzoyl)piperazine. Target compounds were obtained as yellow solid.

2-(4-(4-Chlorobenzoyl)piperazin-1-yl)-3-(phenylsulfonyl) quinoxaline 34. Yield: 32%; mp: 217–219 °C. 1H NMR (500 MHz, CDCl3): δ 8.01 (d, 2H, J = 7.0 Hz, aromatic H), 7.81 (d, 1H, J = 8.0 Hz, aromatic H), 7.73 (t, 1H, J = 7.5 Hz, aromatic H), 7.69-7.65 (m, 2H, aromatic H), 7.57-7.54 (m, 2H, J = 7.5 Hz, aromatic H), 7.51 (t, 1H, J = 7.5 Hz, aromatic H), 7.42 (s, 4H, aromatic H), 4.11-4.07 (m, 2H, piperazine H), 3.70-3.65 (m, 6H, piperazine H). ESI-MS (m/z): 493 [M+H]+.

2-(4-Chlorobenzoyl)piperazin-1-yl)-3-(4-methylphenylsulfonyl) quinoxaline 35. Yield: 32%; mp: 188–190 °C. 1H NMR (500 MHz, CDCl3): δ 7.89 (d, 2H, J = 8.0 Hz, aromatic H), 7.81 (d, 1H, J = 9.0 Hz, aromatic H), 7.72-7.70 (m, 2H, aromatic H), 7.53 (t, 1H, J = 8.0 Hz, aromatic H), 7.42 (s, 4H, aromatic H), 7.35 (d, 2H, J = 8.0 Hz, aromatic H), 4.11-4.04 (m, 2H, piperazine H), 3.80-3.64 (m, 6H, piperazine H), 2.46 (s, 3H, aromatic CH3). ESI-MS (m/z): 507 [M+H]+.

2-(4-Chlorobenzoyl)piperazin-1-yl)-3-(4-methoxyphenylsulfonyl) quinoxaline 36. Yield: 44%; mp: 179 °C. 1H NMR (500 MHz, CDCl3): δ 7.95 (d, 2H, J = 9.5 Hz, aromatic H), 7.80 (d, 1H, J = 9.0 Hz, aromatic H), 7.73 (t, 2H, J = 7.5 Hz, aromatic H), 7.53 (t, 1H, J = 7.5 Hz, aromatic H), 7.43 (s, 4H, aromatic H), 7.02 (d, 2H, J = 9.0 Hz, aromatic H), 6.11-6.04 (m, 2H, piperazine H), 2.86 (s, 3H, aromatic CH3), 2.39 (s, 3H, OCH3). ESI-MS (m/z): 537 [M+H]+.

2-(4-Chlorobenzoyl)piperazin-1-yl)-3-(4-methylphenylsulfonyl) quinoxaline 37. Yield: 26%; mp: 214–216 °C. 1H NMR (500 MHz, CDCl3): δ 7.87 (d, 2H, J = 8.5 Hz, aromatic H), 7.81 (d, 1H, J = 8.0 Hz, aromatic H), 7.74-7.67 (m, 4H, aromatic H), 7.54 (dt, 1H, J = 7.5 and 1.0 Hz, aromatic H), 7.43 (s, 4H, aromatic H), 4.10-4.05 (m, 2H, piperazine H), 3.80-3.66 (m, 6H, piperazine H), ESI-MS (m/z): 573 [M+H]+.

2-(4-Chlorobenzoyl)piperazin-1-yl)-3-(4-fluorophenylsulfonyl) quinoxaline 38. Yield: 38%; mp: 214–215 °C. 1H NMR (500 MHz, CDCl3): δ 8.04 (dd, 2H, J = 9.0 and 5.0 Hz, aromatic H), 7.81 (d, 1H, J = 7.5 Hz, aromatic H), 7.74 (dt, 1H, J = 8.5 and 1.0 Hz, aromatic H), 7.67 (d, 1H, J = 8.5 Hz, aromatic H), 7.53 (dt, 1H, J = 8.5 and 1.0 Hz, aromatic H), 7.43 (s, 4H, aromatic H), 7.26-7.22 (t, 2H, J = 8.5 Hz, aromatic H), 4.12-4.08 (m, 2H, piperazine H), 3.81-3.70 (m, 6H, piperazine H). ESI-MS (m/z): 511 [M+H]+.

General procedure for the synthesis of 39–43. Similar with procedure A, but N-carbamoylpiperazine was replaced by N-(methylsulfonyl)piperazine. Target compounds were obtained as yellow solid.

2-(4-Methylsulfonyl)piperazin-1-yl)-3-(phenylsulfonyl) quinoxaline 39. Yield: 47%; mp: 182–185 °C. 1H NMR (500 MHz, CDCl3): δ 8.01 (d, 2H, J = 7.5 Hz, aromatic H), 7.83 (d, 1H, J = 8.5 Hz aromatic H), 7.72-7.64 (m, 3H, aromatic H), 7.58 (t, 2H, J = 8.0 Hz, aromatic H), 7.52 (dt, 1H, J = 8.0 and 1.0 Hz, aromatic H), 3.84 (t, 4H, J = 4.5 Hz, piperazine H), 3.55 (t, 4H, J = 4.5 Hz, piperazine H), 2.87 (s, 3H, CH3), 2.47 (s, 3H, aromatic CH3), ESI-MS (m/z): 467 [M+H]+.

2-(4-Methylsulfonyl)piperazin-1-yl)-3-(4-methoxyphenylsulfonyl)quinoxaline 40. Yield: 38%; mp: 178–180 °C. 1H NMR (500 MHz, CDCl3): δ 7.89 (d, 2H, J = 8.5 Hz, aromatic H), 7.82 (d, 1H, J = 8.0 Hz, aromatic H), 7.73 (t, 1H, J = 8.0 Hz, aromatic H), 7.69 (d, 1H, J = 8.5 Hz, aromatic H), 7.52 (t, 1H, J = 8.0 Hz, aromatic H), 7.56 (d, 2H, J = 8.0 Hz, aromatic H), 3.84 (t, 4H, J = 4.5 Hz, piperazine H), 3.55 (t, 4H, J = 4.5 Hz, piperazine H), 2.87 (s, 3H, CH3), 2.47 (s, 3H, aromatic CH3), ESI-MS (m/z): 513 [M+H]+.

Piperazinylquinoxalines as PI3K Inhibitors
J = 4.5 Hz, piperazine H), 3.31 (t, 4H, J = 4.5 Hz, piperazine H), 2.45 (s, 3H, aromatic CH3). ESI-MS (m/z): 589 [M+H]+.

2-4-(4-Methylphenylsulfonyl)piperazin-1-yl)-3-(4-fluorophenylsulfonyl)-quinoxaline 48. Yield: 96%; mp: 172-174°C. 1H NMR (500 MHz, CDCl3); δ 7.94 (dd, 2H, J = 7.0 and 5.0 Hz, aromatic H), 7.90 (d, 1H, J = 8.0 Hz, aromatic H), 7.71-7.70 (m, 3H, aromatic H), 7.64 (d, 1H, J = 7.5 Hz, aromatic H), 7.51 (dt, 1H, J = 7.5 and 1.0 Hz, aromatic H), 7.37 (d, 2H, J = 8.5 Hz, aromatic H), 7.18 (t, 2H, J = 8.5 Hz, aromatic H), 3.80 (t, 4H, J = 4.5 Hz, piperazine H), 3.32 (t, 4H, J = 4.5 Hz, piperazine H), 2.45 (s, 3H, aromatic CH3). ESI-MS (m/z): 527 [M+H]+.

General procedure for the synthesis of 49-53. Similar with procedure A, but N-carbamoylpiperazine was replaced by 3-(morpohlinepropyl)piperazine. Target compounds were obtained as yellow mucous substance.

2-4-(3-Morpholinopropyl)piperazin-1-yl)-3-(phenylsulfonyl)-quinoxaline 52. Yield: 78%; 1H NMR (500 MHz, CDCl3); δ 7.86 (d, 2H, J = 8.0 Hz, aromatic H), 7.86 (d, 1H, J = 8.5 Hz, aromatic H), 7.80-7.75 (m, 3H, aromatic H), 7.34 (d, 2H, J = 8.5 Hz, aromatic H), 7.28 (d, 2H, J = 8.0 Hz, aromatic H), 7.22 (t, 2H, J = 8.5 Hz, aromatic H), 3.82 (m, 4H, piperazine H), 3.74 (t, 4H, J = 4.5 Hz, morpholine H), 2.80 (t, 4H, J = 4.5 Hz, morpholine H), 2.57 (t, 2H, J = 7.5 Hz, CH2), 2.49 (m, 4H, piperazine H), 2.46 (t, 2H, J = 7.5 Hz, CH2), 1.84-1.78 (m, 2H, CH2). ESI-MS (m/z): 500 [M+H]+.

MTT Assay - Inhibition of Human Cancer Cell Lines

Human prostate cancer PC3 cells, lung adenocarcinoma epithelial A549 cells, colon cancer HCT116 cells, promyelocytic leukemia HL60 cells and nasopharyngeal carcinoma KB cells were obtained from the cell bank of the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). The inhibitory activity of target compounds against tested cancer cell lines was measured using the MTT assay. PC3, A549, HCT116, HL60, and KB cancer cell lines were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) with heat-inactivated 10% fetal bovine serum, penicillin (100 units/mL) and streptomycin (100 μg/mL) and incubated in an atmosphere with 20% oxygen and 5% carbon dioxide at 37°C. All tested compounds were dissolved in DMSO at concentrations of 10.0 mg/mL and diluted to appropriate concentrations. Cells were plated in 96-well plates for 24 h and subsequently treated with different concentrations of all tested compounds for 72 h. Viable cells were determined using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay kit (MTT, Sigma) according to operation instructions provided by the manufacturer. The concentration of drug causing 50% inhibition in absorbance compared with control cells (IC50) was calculated using the software of dose-effect analysis with microcomputers.

FP Assay - Inhibition of PI3Kα

The PI3Kα inhibitory test was determined using a competitive fluorescence polarization kinase activity assay. PI3K fluorescence polarization assay kit (catalog No. K-1100) and recombinant human PI3Kα (catalog No. E-2000) were purchased from Echelon Biosciences (Salt Lake City, UT, USA). PI3K reactions were performed in 5 mM HEPES, Ph 7, 2.5 mM MgCl2, 10 mM DTT and 50 μM ATP, using diCp-phosphatidylinositol-4, 5-bisphosphate (PIP2) as the substrate, and the final reaction volumes were 10 μL. For evaluation of the PI3Kα inhibitory activity of target compounds, 50 ng enzyme and 10 μM substrate were used per 10 μL reaction volume with the concentrations of inhibitors ranging from 3.2 nM to 10 μM. After incubating for 3 h at room temperature, reactions were quenched by adding chelators. A mixture of phosphoinositide binding protein was added and mixed, followed by the addition of a fluorophore-labeled phosphoinositide tracer. Samples were then mixed in 384-well black Corning nonbinding plates (Corning, NY, USA) and incubated in a dark environment for 1 h to equilibrate. Finally, polarization values were measure using red fluorophores with appropriate filters to determine the extent of enzyme activity in the reaction.

Flow Cytometry Analysis

For flow cytometry analysis, PC3 cells were treated with DMSO, compound 41 and GDC0941 for 24 h. Cells were washed twice with PBS and fixed in 75% ethanol at −20°C. The cell pellet was resuspended in 100 μL of PBS containing 200 mg/mL RNase (Amerson, Solon, OH, USA), then incubated at 37°C for 0.5 h. After incubation, the cells were stained with 20 mL/L propidium iodide (PI, Sigma, St. Louis, MO, USA) at 4°C for 15 min. The fluorescence of cell was measured with FACSCalibur flow cytometer (Becton-Dickinson, Lincoln Park, NJ, USA).
Molecular Docking

The X-ray co-crystal structure of mutant PI3Kα-wortmannin complex was downloaded from the RCSB Protein Data Bank (ID: 3HHM). The C-Dock protocol within DiscoveryStudio 2.1 was utilized to perform molecular docking analysis for compounds 22 and 41. For ligand preparation, the 3D structures of 22 and 41 were generated and minimized using DiscoveryStudio 2.1. For protein preparation, the hydrogen atoms were added, water was removed, and the CHARMM force field was employed. The whole PI3Kα enzyme was defined as a receptor and the site sphere was selected based on the ligand binding location of wortmannin. Compound 22 or 41 were placed in the binding site during the docking procedure. Docking parameters were set as follows: top hits, 25; random conformations, 25; random conformations dynamics steps, 1000; grid extension, 8.0; random dynamics time step, 0.002. All other parameters were set as default values. Types of interactions of the docked enzyme with ligand were analyzed upon the finish of molecular docking. All graphical pictures were made using PyMol.

Acknowledgments

We are thankful to Ms. Jianyang Pan for performing the NMR tests.

Author Contributions

Conceived and designed the experiments: PW YH. Performed the experiments: PW YS YG JZ. Analyzed the data: PW YS XD WH YH. Contributed reagents/materials/analysis tools: PW YS YH. Wrote the paper: PW YH.

References

1. Marone R, Cmiljanovic V, Giese B, Wymann MP (2008) Targeting phosphoinositide 3-kinase – Moving towards therapy. BBA-Proteomics 1784: 159–183.
2. Cantley LC (2002) The Phosphoinositide 3-Kinase Pathway. Science 296: 1655–1657.
3. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606–619.
4. Vanhaesebroeck B, Waterfield MD (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239–254.
5. Denley A, Kang S, Karst U, Vogt PK (2008) Oncogenic signaling of class I PI3K isoforms. Oncogene 27: 2561–2574.
6. Wee S, Wiederschain D, Maira S-M, Loo A, Miller C, et al. (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105: 13057–13062.
7. Kang S, Bader AG, Vogt PK (2003) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102: 4002–4007.
8. Wu P, Liu T, Hu YZ (2009) PI3K inhibitors for cancer therapy: what has been achieved so far? Curr Med Chem 16: 916–930.
9. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550–562.
10. Garcia-Echeverria C, Sellers WR (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511–5526.
11. Wu P, Hu Y (2012) Small molecules targeting phosphoinositide 3-kinases. MedChemComm. doi: 10.1039/C1MD00244A.
12. Wu P, Hu YZ (2010) PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem 17: 4326–4341.
13. Wu P, Su Y, Liu X, Zhang L, Ye Y, et al. (2011) Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3Kα inhibitors. Eur J Med Chem 46: 5540–5548.
14. Wu P, Su Y, Liu X, Yan J, Ye Y, et al. (2012) Discovery of novel morpholinoquinazolines as PI3Kα inhibitors by pharmacophore-based screening MedChemComm 3: 659–662.
15. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-[(3morpholinyl)-6-phenyl-1H-benzo[4,5]imidazol-4-yl] phenol (LY294002). J Biol Chem 269: 5241–5248.
16. Hayakawa M, Kaizawa H, Morimoto H, Koizumi T, Oishi T, et al. (2006) Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 14: 6847–6858.
17. Wu P, Su Y, Liu X, Yang B, He Q, et al. (2012) Discovery of novel 2-piperidinol-3-arylsulfonylquinazolines as phosphoinositide 3-kinase α (PI3Kα) inhibitors. Bioorg Med Chem 20: 2837–2844.
18. Desai M, Wainthry JWH, Zuckerman M (1976) A convenient preparation of 1-arylpyperazinines. Org Prep Proc Int 8: 85–86.
19. Hall HK Jr (1956) Field and inductive effects on the base strengths of amines. J Am Chem Soc 78: 2570–2572.
20. Hu Y, Sheng R, Zhou N, Shi Y, Xu Y, et al. Nitrogen-containing indole derivatives as histamine H3 receptor antagonists or agonists and their preparation. CN 2009/10136719.
21. Drees BE, Weigert A, Holland H, Ferguson CG, Chakaravarty L, et al. (2003) Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity. Comb Chem High Throughput Screening 6: 321–330.
22. Abad-Zapatero G, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10: 464–469.
23. Folkes AJ, Ahnadki K, Alderton WK, Arix S, Baker SJ, et al. (2008) The identification of 2-[1H-indazol-4-yl]-6-[4-methanesulfonyl-piperazin-1-ylmethyl]-4- morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51: 5322–5332.
24. Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu J, Cheong I, et al. (2009) A frequent kinase domain mutation that changes the interaction between PIK3α and the membrane. Proc Natl Acad Sci USA 106: 16996–17001.
25. Walker EH, Paolc ME, Periscic O, Stephens I, Hawkins PT, et al. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6: 909–919.